Targeted cancer therapy: What if the driver is just a messenger?

Jonathan H Schatz, Hans Guido Wendel

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

"Shoot the driver" is the paradigm of targeted cancer therapy. However, resistance to targeted inhibitors of signaling pathways is a major problem. In part the redundancy of signaling networks can bypass targeted inhibitors and thereby reduce their biological effect. In this case the driver turns out to be one of several potential messengers and is easily replaced. Cocktails of multiple targeted inhibitors are an obvious solution. This is limited, however, by the lack of potent inhibitors and may also produce increased toxicity. Therefore we explored the direct blockade of a key biological activity downstream from multiple converging oncogenic signals. Specifically, several oncogenic signaling pathways including AKT, MAPK and PIM kinase signals converge on the activation of capdependent translation. In cancer cells, aberrant activation of cap-dependent translation favors the increased expression of short-lived oncoproteins like c-MYC, MCL1, CYCLIN D1 and the PIM kinases. Intriguingly, cancer cells are especially sensitive to even temporary reductions in these proteins. We will discuss our findings concerning translational inhibitor therapy in cancer.

Original languageEnglish (US)
Pages (from-to)3830-3833
Number of pages4
JournalCell Cycle
Volume10
Issue number22
DOIs
StatePublished - Nov 15 2011
Externally publishedYes

Fingerprint

Neoplasms
Oncogene Proteins
Mitogen-Activated Protein Kinase Kinases
Therapeutics
Phosphotransferases
Proteins

Keywords

  • Cancer
  • eIF4E
  • Lymphoma
  • Targeted therapy
  • Translation

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Developmental Biology

Cite this

Targeted cancer therapy : What if the driver is just a messenger? / Schatz, Jonathan H; Wendel, Hans Guido.

In: Cell Cycle, Vol. 10, No. 22, 15.11.2011, p. 3830-3833.

Research output: Contribution to journalArticle

Schatz, Jonathan H ; Wendel, Hans Guido. / Targeted cancer therapy : What if the driver is just a messenger?. In: Cell Cycle. 2011 ; Vol. 10, No. 22. pp. 3830-3833.
@article{df6c3728b74545c08aca8ffba8f08750,
title = "Targeted cancer therapy: What if the driver is just a messenger?",
abstract = "{"}Shoot the driver{"} is the paradigm of targeted cancer therapy. However, resistance to targeted inhibitors of signaling pathways is a major problem. In part the redundancy of signaling networks can bypass targeted inhibitors and thereby reduce their biological effect. In this case the driver turns out to be one of several potential messengers and is easily replaced. Cocktails of multiple targeted inhibitors are an obvious solution. This is limited, however, by the lack of potent inhibitors and may also produce increased toxicity. Therefore we explored the direct blockade of a key biological activity downstream from multiple converging oncogenic signals. Specifically, several oncogenic signaling pathways including AKT, MAPK and PIM kinase signals converge on the activation of capdependent translation. In cancer cells, aberrant activation of cap-dependent translation favors the increased expression of short-lived oncoproteins like c-MYC, MCL1, CYCLIN D1 and the PIM kinases. Intriguingly, cancer cells are especially sensitive to even temporary reductions in these proteins. We will discuss our findings concerning translational inhibitor therapy in cancer.",
keywords = "Cancer, eIF4E, Lymphoma, Targeted therapy, Translation",
author = "Schatz, {Jonathan H} and Wendel, {Hans Guido}",
year = "2011",
month = "11",
day = "15",
doi = "10.4161/cc.10.22.18288",
language = "English (US)",
volume = "10",
pages = "3830--3833",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "22",

}

TY - JOUR

T1 - Targeted cancer therapy

T2 - What if the driver is just a messenger?

AU - Schatz, Jonathan H

AU - Wendel, Hans Guido

PY - 2011/11/15

Y1 - 2011/11/15

N2 - "Shoot the driver" is the paradigm of targeted cancer therapy. However, resistance to targeted inhibitors of signaling pathways is a major problem. In part the redundancy of signaling networks can bypass targeted inhibitors and thereby reduce their biological effect. In this case the driver turns out to be one of several potential messengers and is easily replaced. Cocktails of multiple targeted inhibitors are an obvious solution. This is limited, however, by the lack of potent inhibitors and may also produce increased toxicity. Therefore we explored the direct blockade of a key biological activity downstream from multiple converging oncogenic signals. Specifically, several oncogenic signaling pathways including AKT, MAPK and PIM kinase signals converge on the activation of capdependent translation. In cancer cells, aberrant activation of cap-dependent translation favors the increased expression of short-lived oncoproteins like c-MYC, MCL1, CYCLIN D1 and the PIM kinases. Intriguingly, cancer cells are especially sensitive to even temporary reductions in these proteins. We will discuss our findings concerning translational inhibitor therapy in cancer.

AB - "Shoot the driver" is the paradigm of targeted cancer therapy. However, resistance to targeted inhibitors of signaling pathways is a major problem. In part the redundancy of signaling networks can bypass targeted inhibitors and thereby reduce their biological effect. In this case the driver turns out to be one of several potential messengers and is easily replaced. Cocktails of multiple targeted inhibitors are an obvious solution. This is limited, however, by the lack of potent inhibitors and may also produce increased toxicity. Therefore we explored the direct blockade of a key biological activity downstream from multiple converging oncogenic signals. Specifically, several oncogenic signaling pathways including AKT, MAPK and PIM kinase signals converge on the activation of capdependent translation. In cancer cells, aberrant activation of cap-dependent translation favors the increased expression of short-lived oncoproteins like c-MYC, MCL1, CYCLIN D1 and the PIM kinases. Intriguingly, cancer cells are especially sensitive to even temporary reductions in these proteins. We will discuss our findings concerning translational inhibitor therapy in cancer.

KW - Cancer

KW - eIF4E

KW - Lymphoma

KW - Targeted therapy

KW - Translation

UR - http://www.scopus.com/inward/record.url?scp=81855212716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855212716&partnerID=8YFLogxK

U2 - 10.4161/cc.10.22.18288

DO - 10.4161/cc.10.22.18288

M3 - Article

C2 - 22064518

AN - SCOPUS:81855212716

VL - 10

SP - 3830

EP - 3833

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 22

ER -